SCHEMBL3487237

SCHEMBL3487237

O=C(O)c1ccc(-c2ccc(-c3cc4ccccc4o3)[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
TNKS O95271 1/20 0.49
CSNK2A1 P68400 1/20 0.48
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NFKB1 P19838 1/20 0.45
NPY1R P25929 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
MAPT P10636 1/20 0.45
ALOX5 P09917 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980203 0.84 TNKS (0.66) TNKSCSNK2A1RAB9ANPC1SMN1; SMN2
SCHEMBL7618483 0.83 KDM4E (0.46) RAB9ANPC1KDM4EALDH1A1KMT2A
SCHEMBL7618637 0.81 RARA (0.50) TNKSRAB9ANPC1MAOBMAOA
SCHEMBL7618545 0.80 TNKS (0.48) TNKSRARARARBRARGNQO2
SCHEMBL7625464 0.80 RARA (0.44) RAB9ANPC1RARARARBRARG
SCHEMBL7624863 0.80 MAOB (0.51) RAB9ANPC1MEN1KMT2AMAOB
SCHEMBL7625527 0.80 TNKS (0.48) TNKSRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7725462 0.78 RARA (0.41) TNKSKDM4EALDH1A1KMT2AMAPT
SCHEMBL7628810 0.78 RARA (0.54) KDM4EALDH1A1KMT2AMAPTRARA
SCHEMBL7618653 0.78 RARA (0.42) RAB9ANPC1TP53MAPTRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063162-A1 METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-03-11 US disclosed
EP-1950293-A1 METHOD FOR PREDICTION OF EFFECTIVENESS OF RAR- AGONIST Taiho Pharmaceutical Co., Ltd. (JP) 2008-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063162-A1 METHOD FOR PREDICTING EFFICACY OF RAR-ALPHA AGONIST RARA, RARB, RARG KDM5A 3610/4885KDM4C 4295/4885KDM5B 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.